As investigators evaluate novel peptide compounds in host defense and respiratory epithelial models, securing a verified reference material supplier is critical. PX1 Research delivers analytical-grade Bronchogen synthesized under strict US quality standards, verified by HPLC and mass spectrometry for rigorous in vitro and preclinical research applications.
As investigators evaluate novel peptide compounds in host defense and respiratory epithelial models, securing a verified reference material supplier is critical. PX1 Research delivers analytical-grade Bronchogen synthesized under strict US quality standards, verified by HPLC and mass spectrometry for rigorous in vitro and preclinical research applications.
A reliable bronchogen antiviral strategies supplier provides research laboratories with analytical-grade Ala-Glu-Asp-Leu tetrapeptide featuring fully documented purity (≥98%), low endotoxin content (<0.01 EU/mg), and lot-specific certificates of analysis. Researchers evaluate Bronchogen in preclinical models to investigate respiratory epithelial gene expression, chromatin condensation, and mucosal host defense mechanisms against viral pathogen challenges.
In laboratory settings, acquiring synthetic regulatory peptides requires strict quality control to ensure reproducible baseline measurements across cell culture assays, organoid models, and animal tissue studies. PX1 Research supports institutional research by supplying US-manufactured compounds validated via RP-HPLC and mass spectrometry.
Bronchogen is a synthetic short-chain peptide composed of four amino acid residues: L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). Categorized within the class of peptide bioregulators, this specific sequence was derived from chromatin-binding investigations designed to analyze site-specific interaction between low-molecular-weight peptides and double-stranded DNA.
Preclinical binding assays indicate that short peptides like Bronchogen can permeate cell membranes and nuclear envelopes without requiring active transport systems. Upon entering the nucleus, the tetrapeptide selectively binds to histone proteins and specific nucleotide sequences in promoter regions of target genes. In cell-free nucleosome models, this binding modulates chromatin accessibility, altering transcription factor recruitment to genes governing bronchial epithelial cell differentiation, mucociliary clearance, and cytoprotective protein synthesis.
Understanding these primary chemical parameters is vital when designing assays in our research library hub, where investigators explore peptide-genome interactions and epigenetic modulation mechanisms.
In vitro data indicate that Bronchogen plays a key role in modulating cellular responses within bronchial epithelial cell cultures exposed to stress factors. Primary human bronchial epithelial (HBE) cell assays demonstrate that application of the peptide leads to an upregulation of gene expression related to surfactant protein synthesis, structural tubulin, and junctional complex integrity. Maintaining these cellular structures is vital for mucosal barrier function during viral exposure.
In animal study models evaluating lung tissue damage caused by oxidative or pathogen-induced challenges, administration of synthetic Bronchogen demonstrated a reduction in proinflammatory cytokine expression, specifically dampening TNF-alpha, IL-6, and IL-8 release. Concurrently, tissue homogenates exhibited enhanced expression of endogenous antioxidant enzymes, including superoxide dismutase (SOD) and catalase.
Furthermore, preclinical viral challenge models examining respiratory syncytial virus (RSV) and influenza strains suggest that cell cultures pre-treated with Bronchogen show preserved ciliary beat frequency and reduced viral plaque formation. Researchers hypothesize that this effect is mediated not by direct virucidal activity, but by the stabilization of host cell mucosal architecture and upregulation of local innate host defense peptides. For related investigations into innate immunity, explore our complete catalog of research peptides.
When designing experimental antiviral strategies, modern respiratory research increasingly focuses on host-directed therapies rather than direct-acting antiviral molecules. Direct antiviral agents often select for resistant viral mutations; conversely, host-directed peptide strategies target conserved cellular mechanisms that viruses exploit during entry and replication.
Investigative frameworks using Bronchogen examine several distinct host-factor regulatory pathways:
1. Epithelial Barrier Stabilization: Quantifying trans-epithelial electrical resistance (TEER) in primary air-liquid interface (ALI) cultures exposed to viral mimic poly(I:C) or live viral vectors.
2. Inflammatory Signaling Attenuation: Measuring NF-kB nuclear translocation kinetics and downstream chemokines in pulmonary macrophages and parenchymal cells.
3. Epigenetic Gene Activation: Evaluating histone acetylation marks (e.g., H3K9ac and H3K4me3) near promoter sites for host defense proteins.
By utilizing analytical-grade Bronchogen, research teams can accurately isolate these host defense pathways without interference from synthetic impurities or variable peptide degradation products.
In bioregulatory peptide research, short-chain amino acid sequences are categorized based on their tissue tropism and target organ specificity. While Bronchogen exhibits targeted activity toward bronchial and pulmonary tissue structures, neighboring synthetic peptides focus on alternative physiological systems.
Comparative preclinical studies highlight key functional distinctions among related bioregulatory compounds:
• Bronchogen (Ala-Glu-Asp-Leu): Specifically targets bronchial epithelial cells, mucociliary repair pathways, and pulmonary cytokine balance.
• Thymogen (Glu-Trp): Focuses primarily on T-lymphocyte differentiation, systemic immune system regulation, and thymus-derived cellular responses.
• Chonluten (Glu-Asp-Gly): Evaluated alongside Bronchogen in pulmonary tissue models, demonstrating synergistic effects on extracellular matrix restoration and connective tissue integrity in chronic lung remodeling models.
• Epitalon (Ala-Glu-Asp-Gly): Acts predominantly on pineal gland chromatin regulation, telomerase activity modulation, and systemic neuroendocrine homeostasis.
Selecting the correct bioregulatory sequence depends on the targeted cell population and the physiological endpoints specified in the laboratory protocol.
To ensure experimental validity, high-purity lyophilized Bronchogen must be reconstituted following precise laboratory procedures. Lyophilized peptide cakes should be brought to room temperature in a desiccator prior to opening to avoid moisture condensation on the cake surface.
Reconstitution guidelines for analytical research:
1. Solvent Selection: Use sterile, bacteriostatic water for injection or sterile phosphate-buffered saline (PBS, pH 7.4). For sensitive cell culture protocols requiring solvent-free solutions, standard sterile 0.9% sodium chloride is recommended.
2. Addition Protocol: Gently introduce the solvent down the inner glass wall of the vial using a precision pipettor. Avoid high-pressure injection directly onto the lyophilized powder cake.
3. Solubilization: Gently swirl or roll the vial between palms until full dissolution is achieved. Never subject peptide solutions to high-speed vortexing, which can induce physical shearing of the peptide bond structure or cause molecular aggregation.
4. Aliquoting: Once fully dissolved, aliquot the stock solution into single-use microcentrifuge tubes to prevent degradation caused by repeated freeze-thaw cycles. Detailed parameters are accessible in our guide on peptide reconstitution protocols.
Synthetic peptides are vulnerable to chemical degradation via hydrolysis, oxidation, and diketopiperazine formation if improperly stored. In its lyophilized state, Bronchogen exhibits high stability when maintained at -20°C in a dry environment protected from light.
For long-term archival storage (>12 months), storage at -80°C is recommended. Reconstituted aqueous stock solutions should be kept at 2°C to 8°C for short-term experimentation not exceeding 7 days. If extended storage of reconstituted solutions is necessary, keep sub-aliquots frozen at -80°C and limit usage to a single thaw event. Avoid non-frost-free freezers, as thermal cycling during automated defrost cycles rapidly accelerates peptide hydrolysis.
Securing reliable data in antiviral research depends directly on the chemical purity and batch consistency of reference peptides. Substandard synthesis can introduce truncated peptide sequences, residual coupling reagents, heavy metals, or toxic bacterial endotoxins—all of which invalidate sensitive cell viability and gene expression assays.
Key criteria for evaluating a research peptide supplier:
• High-Performance Liquid Chromatography (RP-HPLC): Verification that the target peptide peak constitutes ≥98% of total UV absorbance area at 214/220 nm.
• Mass Spectrometry (MS): Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF confirming the exact molecular mass (444.44 g/mol) matches the theoretical molecular weight.
• Endotoxin Quantitation: Chromogenic Limulus Amebocyte Lysate (LAL) testing guaranteeing endotoxin levels strictly below <0.01 EU/mg, preventing false-positive inflammatory readouts in cell culture.
• Domestic Supply Infrastructure: Sourcing from US-manufactured facilities that maintain ISO 17025 standard laboratory testing and GMP-compliant synthesis protocols.
PX1 Research operates as a dedicated provider of analytical-grade reference compounds for academic, government, and private research entities. Every batch of Bronchogen supplied undergoes independent, third-party verification to confirm structural identity and purity profiles.
We provide transparent documentation with every order, including lot-specific Certificates of Analysis (COAs) containing full RP-HPLC chromatograms and mass spectra. Products are synthesized in state-of-the-art US facilities utilizing automated solid-phase peptide synthesis (SPPS) equipment, followed by multi-step purification and lyophylization.
To support institutional research timelines, PX1 Research maintains centralized inventory management with same-day dispatch from our California and Arizona logistics facilities. Laboratories seeking high-volume requisitions or ongoing assay supplies can coordinate directly via our wholesale lab account portal.
What is the primary mechanism of Bronchogen in respiratory research models?
Preclinical studies suggest Bronchogen (Ala-Glu-Asp-Leu) interacts directly with nuclear chromatin in bronchial epithelial cells, modulating promoter access and upregulating expression of mucosal barrier proteins, tubulin, and endogenous antioxidant enzymes.
How is Bronchogen purity verified by PX1 Research?
Every lot of Bronchogen undergoes rigorous analytical testing including Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination (≥98%) and Mass Spectrometry (ESI-MS) for molecular weight confirmation, documented on a downloadable lot-specific COA.
What endotoxin controls are applied to Bronchogen reference standards?
PX1 Research subjects all peptide batches to LAL chromogenic endotoxin testing. Our research-grade Bronchogen measures under 0.01 EU/mg to prevent non-specific immune activation in sensitive in vitro cellular assays.
How should lyophilized Bronchogen be stored upon receipt?
Upon arrival, lyophilized Bronchogen should be stored at -20°C in a dry environment away from light. For storage exceeding 12 months, temperature control at -80°C is recommended to preserve chemical stability.
Can Bronchogen be reconstituted directly in cell culture media?
While possible, best practice dictates reconstituting the lyophilized peptide first in sterile, deionized water or sterile PBS (pH 7.4) to form a concentrated stock solution, which is then diluted into culture media to ensure precise concentration control.
What related bioregulatory peptides are used in respiratory studies?
In addition to Bronchogen, researchers frequently evaluate Chonluten (Glu-Asp-Gly) for tissue remodeling studies and Thymogen (Glu-Trp) for innate immune pathway modulation.
Is Bronchogen approved for therapeutic or clinical application?
No. Bronchogen provided by PX1 Research is strictly designated for laboratory research use only. It is not intended, labeled, or supplied for human, medical, clinical, or diagnostic applications.
Where does PX1 Research ship Bronchogen orders from?
All PX1 Research orders are packaged under strict laboratory conditions and shipped directly from our inventory hubs in California and Arizona, with same-day shipping for orders placed before daily cutoff times.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.